Preclinical data have demonstrated that TNF-α blockade promotes the infiltration of activated T cells induced by ICI treatment and that combination therapy with anti–CTLA-4 and anti–PD-1 with TNF-α blockade improves tumor responses and decreases irAEs in mouse models of melanoma and colon cancer [24,27,28,29]. This evidence concerns the gene CTLA4 and melanoma.